Search

Displaying results 2561 - 2570 of 2959 in total
  1. Drug

    BMS-564929

    go.drugbank.com/drugs/DB07286
    Experimental

    So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.

  2. Drug

    Thymalfasin

    go.drugbank.com/drugs/DB04900
    Investigational

    Thymalfasin is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an acetylated polypeptide. Thymosin alpha 1 is now approved in 35 developing countries for the treatment...

  3. Drug

    Denufosol

    go.drugbank.com/drugs/DB04983
    Investigational

    Denufosol has not gained FDA approval, and clinical trials with this drug have ceased since 2011. … A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol.

  4. Drug

    Olopatadine

    go.drugbank.com/drugs/DB00768
    Approved

    An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively.

  5. Drug

    Glycopyrronium

    go.drugbank.com/drugs/DB00986
    ApprovedInvestigationalVet approved

    [A233565] Glycopyrronium was originally granted FDA approval on 11 August 1961.[L33090]

  6. Drug

    Hyaluronic acid

    go.drugbank.com/drugs/DB08818
    ApprovedInvestigationalVet approved

    [A230133] Several preparations of hyaluronic acid have been approved by the FDA and are available in oral, topical, and injectable forms.

    Products: E- Repair
  7. Drug

    Plasma protein fraction (human)

    go.drugbank.com/drugs/DB13968
    ApprovedInvestigational

    [A32512] It is already reviewed under the category of biologics by the FDA where the processing, required tests, requirements and labeling are incorporated.

  8. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    [L63934] The FDA approved centanafadine on July 24, 2026, for the treatment of ADHD in adults and pediatric patients 6 years of age and older weighing at least 20 kg; use is not recommended below that

  9. Drug

    Retifanlimab

    go.drugbank.com/drugs/DB15766
    ApprovedInvestigational

    [L45608,L45618] On March 2023, the FDA granted accelerated approval to retifanlimab for a different indication, the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).

  10. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic